We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





New Groundbreaking COVID-19 Test to Identify SARS-CoV-2 Virus Particles in Exhaled Breath Within Five Minutes

By LabMedica International staff writers
Posted on 27 Oct 2020
Researchers are developing a SARS-CoV-2 test to identify positive cases and confirm whether someone is contagious in less than five minutes using a groundbreaking approach that will use virus particles in exhaled breath.

Imec (Leuven, Belgium) has begun developing the groundbreaking SARS-CoV-2 test that will identify the virus particles in a person's exhaled breath, unlike the current approaches (using blood, saliva, or a nasopharyngeal swab). More...
The solution promises accurate identification of a contagious case in less than five minutes, enabling faster, easier, more comfortable, and larger-scale testing. Imec's solution consists of a sample collector and an analysis unit, both of which are being custom developed by Imec researchers. Researchers are focusing much of their attention on the sample collector, which will act as the aerosol (and virus particle) collector and support the solution's high-speed real-time quantitative (RT-q) PCR functionality.

“Merging these tasks using conventional technologies would be extremely hard to do. But thanks to our innovation capability when it comes to using silicon, we have developed a chip that effectively does both,” said Peter Peumans, CTO of Health Technologies at Imec. “Its silicon microscale PCR cavities make for thousands of impactors that allows us to capture the viral particles, while its powerful RT-qPCR functionality brings down the duration of the PCR effort from 50 to 5 minutes. Importantly as well, the standard silicon technology used to build this chip facilitates mass production at a low cost.”

"Provided positive results in our clinical studies, our tool will make testing for SARS-CoV-2 easier, faster, more comfortable, and possible on a much larger scale. Moreover, we are designing our test to flexibly cope with the rise of other viruses and germs that spread via exhaled particles – such as influenza, RSV, and tuberculosis," added Peumans.

“It is now clear that the virus is transmitted pre-symptomatically via exhaled particles,” said Peter Piot, microbiologist and member of the European Commission advisory panel on COVID-19. “SARS-CoV-2 testing via breath sample coupled with an ultrafast molecular analysis would be game-changing since it would allow for the timely detection of individuals who are most likely to transmit the virus. Because a breath sample is much less invasive compared to swabs or saliva, it would also allow for more frequent testing and a faster return to normal.”

Related Links:
Imec


Platinum Member
Fully Automatic ACLIA Analyzer
MAGLUMI X8
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
New
Next-Generation Sequencing Platform
AXELIOS 1 Platform
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical Abstract (Ziegler, AG., Rewers, M.J., Achenbach, P. et al. Diabetologia (2026). https://doi.org/10.1007/s00125-026-06841-z)

International Consensus Guidance Outlines General Population Screening for Early-Stage Type 1 Diabetes

Type 1 diabetes (T1D) is an autoimmune disease that can develop in childhood or adulthood and affects an estimated 9.5 million people worldwide. Its complications range from acute diabetic ketoacidosis... Read more

Microbiology

view channel
Image: The current BDBV outbreak in the DRC underscores response challenges for rare, severe infections (Image Credit: 123RF)

Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics

Bundibugyo virus (BDBV), a species of ebolavirus, causes severe hemorrhagic disease and can be difficult to diagnose rapidly during outbreaks. Recent regulatory changes have further complicated swift deployment... Read more

Technology

view channel
Image: The 5811 R retains the performance and versatility of its predecessor while adding a new design, a refreshed user interface, and updated sustainable cooling technology. (Photo courtesy of Eppendorf)

New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling

Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more

Industry

view channel
Image: The combined offering is designed to streamline workflows and support multicolor applications used in leukemia, lymphoma, and measurable residual disease assessment in specialized clinical settings

Sysmex and Cytek Collaboration Expands Access to Advanced Clinical Flow Cytometry

Sysmex Europe SE (Hamburg, Germany) and Cytek Biosciences (Fremont, CA, USA) are partnering across more than a dozen European countries to expand access to advanced clinical flow cytometry.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.